Data From Phase III Extension Trial Show Long-Term Safety, Efficacy of Qulipta in Migraine Prevention; Multicenter, open-label, 156-week extension trial finds that Qulipta (atogepant) reduced migraine days and acute medication use in patients with chronic

  • Sait Ashina

Press/Media

Period12 Apr 2024

Media coverage

1

Media coverage

  • TitleData From Phase III Extension Trial Show Long-Term Safety, Efficacy of Qulipta in Migraine Prevention; Multicenter, open-label, 156-week extension trial finds that Qulipta (atogepant) reduced migraine days and acute medication use in patients with chronic
    Media name/outletApplied Clinical Trials
    Country/TerritoryUnited States
    Date12/04/24
    PersonsSait Ashina